BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 12040295)

  • 1. Phase II trial of KW2189 in patients with advanced malignant melanoma.
    Markovic SN; Suman VJ; Vukov AM; Fitch TR; Hillman DW; Adjei AA; Alberts SR; Kaur JS; Braich TA; Leitch JM; Creagan ET
    Am J Clin Oncol; 2002 Jun; 25(3):308-12. PubMed ID: 12040295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma.
    Small EJ; Figlin R; Petrylak D; Vaughn DJ; Sartor O; Horak I; Pincus R; Kremer A; Bowden C
    Invest New Drugs; 2000 May; 18(2):193-7. PubMed ID: 10857997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
    García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
    Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
    Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
    Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
    McDermott DF; Mier JW; Lawrence DP; van den Brink MR; Clancy MA; Rubin KM; Atkins MB
    Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
    Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.
    Steffens TA; Bajorin DF; Chapman PB; Lovett DR; Cody-Johnson BV; Templeton MA; Heelan RT; Wong GY; Portlock CS; Oettgen HF
    Cancer; 1991 Sep; 68(6):1230-7. PubMed ID: 1873774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of Didemnin B (NSC 325319) in advanced malignant melanoma: an Eastern Cooperative Oncology Group study (PB687).
    Hochster H; Oratz R; Ettinger DS; Borden E
    Invest New Drugs; 1998-1999; 16(3):259-63. PubMed ID: 10360606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks.
    Alberts SR; Erlichman C; Reid JM; Sloan JA; Ames MM; Richardson RL; Goldberg RM
    Clin Cancer Res; 1998 Sep; 4(9):2111-7. PubMed ID: 9748127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.
    Eisen T; Thomas J; Miller WH; Gore M; Wolter P; Kavan P; Martín JA; Lardelli P
    Melanoma Res; 2009 Jun; 19(3):185-92. PubMed ID: 19436178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detorubicin--an active anthracycline in untreated metastatic melanoma.
    Chawla SP; Legha SS; Benjamin RS
    J Clin Oncol; 1985 Nov; 3(11):1529-34. PubMed ID: 4056844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Ozols RF
    J Clin Oncol; 1995 Aug; 13(8):1860-70. PubMed ID: 7543559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma.
    Locke F; Clark JI; Gajewski TF
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):509-14. PubMed ID: 19597729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma.
    Smylie MG; Wong R; Mihalcioiu C; Lee C; Pouliot JF
    Invest New Drugs; 2007 Apr; 25(2):155-9. PubMed ID: 16957835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study.
    Whitehead RP; Moon J; McCachren SS; Hersh EM; Samlowski WE; Beck JT; Tchekmedyian NS; Sondak VK;
    Cancer; 2004 Apr; 100(8):1699-704. PubMed ID: 15073859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma.
    Burdette-Radoux S; Tozer RG; Lohmann RC; Quirt I; Ernst DS; Walsh W; Wainman N; Colevas AD; Eisenhauer EA
    Invest New Drugs; 2004 Aug; 22(3):315-22. PubMed ID: 15122079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of carboplatin in patients with metastatic malignant melanoma. A report from the Eastern Cooperative Oncology Group.
    Chang A; Hunt M; Parkinson DR; Hochster H; Smith TJ
    Am J Clin Oncol; 1993 Apr; 16(2):152-5. PubMed ID: 8452109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma.
    Pierson AS; Gibbs P; Richards J; Russ P; Eckhardt SG; Gonzalez R
    Invest New Drugs; 2002 Aug; 20(3):357-62. PubMed ID: 12201500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.